PVLA PALVELLA THERAPEUTICS INC

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.

Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update.

To access the live webcast of the call with slides, please click or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this , and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at .

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on or (formerly known as Twitter).

QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen

Founder and CEO, Palvella Therapeutics

Media

Marcy Nanus

Managing Partner, Trilon Advisors, LLC



EN
08/05/2025

Underlying

PVLAPALVELLA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALVELLA THERAPEUTICS INC

 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics to Host First Quarter 2025 Financial Results and...

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on...

11h / 48m 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that the Company will ring the opening bell at the Nasdaq Stock Market (Nasdaq) on Monday, May 12, 2025 in New York City. Wes Kaupinen, Founder and Chief Executi...

May 5, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Announces Abstract Highlighting the Estimated Di...

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation Poster to be presented on Thursday, May 8, 2025, 4:30-6:00 pm PT ...

April 23, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapam...

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...

April 22, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel f...

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial Top-line results from SEL...

April 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch